7-[3-(1-piperidinyl)propoxy]chromenones as potential atypical antipsychotics

Journal of Medicinal Chemistry

Volumn 39, Issue 15, 1996, Pages 2962-2970

  Bolós, Jordi ^a,b   Gubert, Santiago ^a,b   Anglada, Lluís ^a,b   Planas, Josep M ^a,b   Burgarolas, Carme ^a,b   Castelló, Josep M ^a   Sacristán, Aurelio ^a   Ortiz, José A ^a  

^a Centro de Investigaciones Farmaceuticos Grupo Ferrer   (Spain)

^b Department of Medicinal Chemistry ^*

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; CHROMENE DERIVATIVE; CLOZAPINE; ETHYLENEDIAMINE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; REMOXIPRIDE; RISPERIDONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALEPSY; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG STRUCTURE; EXTRAPYRAMIDAL SYMPTOM; HYPERACTIVITY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PSYCHOSIS; SCHIZOPHRENIA; STEREOTYPY;

ADMINISTRATION, ORAL; ANIMALS; ANTIPSYCHOTIC AGENTS; APOMORPHINE; BEHAVIOR, ANIMAL; BIOLOGICAL AVAILABILITY; CATALEPSY; CHROMONES; MALE; MICE; MOLECULAR STRUCTURE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; STEREOTYPED BEHAVIOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0029898606     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950894b     Document Type: Article

References (30)

1. Marder, S. R.; Wirshing, W. C.; Van Putten, T. Drug treatment of schizophrenia - overview of recent research. Schizophr. Res. 1991, 4 (2), 81-90.
2. Baldessarini, R. J.; Frankenburg, F. R. Clozapine: a novel antipsychotic agent. N. Engl. J. Med. 1991, 324, 746-754.
3. Grohmann, R.; Schmidt, L. G.; Spieb-Kiefer, C.; Rüther, E. Agranulocytosis and significant leucopenia with neuroleptic drugs: results from the AMÜP program. Psychopharmacology 1989, 99, S109-112.
4. Ogren, S. O.; Hall, H.; Köhler, C.; Magnusson, O.; Lindbom L.-O.; Angeby, T.; Florvall, L. Remoxipride, a new potential antipsychotic compound with selective anti-dopaminergic actions in the rat brain. Eur. J. Pharmacol. 1984, 102, 459-474.
5. 2 antagonistic properties. J. Pharmacol. Exp. Ther. 1988, 244 (2), 685-693.
6. Philpott, N. J.; Marsh, J. C. W.; Gordon-Smith, E. C.; Bolton, J. S.; Laidlaw, S. T.; Snowden, J. A.; Brown, M. J. Aplastic anaemia and remoxipride. Lancet 1993, 342, 1244-1245.
7. Davis, K. L.; Kahn, R. S.; Ko, G.; Davidson, M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 1991, 148 (11), 1474-1486.
8. Creese, I.; Burt, D. R.; Snyder, S. H. Dopamine receptor binding predicts clinical and pharmacological potencies of antipsychotic drugs. Science 1976, 192, 481-483.
9. Costall, B.; Naylor, R. J. The importance of ascending dopaminergic systems to the extrapyramidal and mesolimbic brain areas for the cataleptic action of neuroleptic and cholinergic agents. Neuropharmacology 1974, 13, 353-364.
10. West, S. A.; Nemeroff, C. B. Atypical antipsychotic drugs: current status and future directions. Drugs Today 1993, 29 (3), 183-188.
11. 2 affinities differentiate atypical and typical antipsychotic drugs. Psychopkarmacol. Bull. 1989, 25 (3), 390-392.
12. Walker, J. M.; Bowen, W. D.; Walker, F. O.; Matsumoto, R. R.; De Costa, B.; Rice, K. Sigma receptors: biology and function. Pharmacol. Rev. 1990, 42, 355-402.
13. Kilts, C. D.; Anderson, C. M.; Bissette, G.; Ely, T. D.; Nemeroff, C. B. Different effects of antipsychotic drugs on the neurotensin content of discrete brain nuclei. Biochem. Pharmacol. 1988, 37, 1547-1554.
14. Moore, N. C.; Gershon, S. Which atypical antipsychotics are identified by screening tests? Clin. Neuropharmacol. 1989, 12, 167-184.
15. Foguet, R.; Gubert, S.; Ortiz, J. A.; Sacristán, A.; Castelló, J. M. Span. Patent 9501182, 1995.
16. (a) Duff, J. G.; Jung, D. K. Synthesis of some unsymmetrical 1,4-disubstituted-2-methylpiperazine. Can. Pharm. J. 1962, 95, 256-259.
17. (b) Cignarella, G.; Loriga, M.; Paglietti, G. C-Alkylpiperazines. Farmaco, Ed. Sci. 1979, 34, 817-823.
18. (a) Godefroi, E. F. The reductive ring cleavage of 1,3-disubstituted imidazolium iodides by sodium borohydride. J. Org. Chem. 1968, 33, 860-862.
19. (b) Krapcho, J.; Turk, C. F. Analgesics. Basic amides of oc-alkoxydiphenylaeetic acids. J. Med. Chem. 1963, 6, 547-550.
20. Duncan, R. L.; Helsley, G. C.; Welstead, W. J.; DaVanzo, J. P.; Funderburk, W. H.; Lunsford, C. D. Aroylpiperidines and pyrrolidines. A new class of potent central nervous system depressants. J. Med. Chem. 1970, 73, 1-6.
21. Wick, A.; Frost, J.; Gaudilliere, B.; Bertin, J.; Dupont, R.; Rousseau, J. Fr. Patent 2,534,580, 1984.
22. Bheemasankara Rao, C.; Subramanyam, G.; Venkateswarlu, V. Synthesis of chromones. II. Some derivatives of 7-hydroxy-2-methylchromone. J. Org. Chem. 1959, 24, 683-4.
23. Robinson, R.; Venkataraman, K. A synthesis of acacetin and certain other derivatives of flavone. J. Chem. Soc. 1926, 2344-2348.
24. Jaen, J. C.; Wise, L. D.; Heffner, T. G.; Pugsley, T. A.; Meltzer, L. T. Dopamine autoreceptor agonists as potential antipsychotics. 2. (Aminoalkoxy)-4H-1-benzopyran-4-ones. J. Med. Chem. 1991, 34, 248-256.
25. Jain, A. C.; Tyagi, O. D.; Saksena, R. A new synthesis of 3-methylchromones. Indian J. Chem., Sect. B 1989, 28B (8), 678-9.
26. J. M. Planas, unpublished results.
27. Protais, P.; Costentin, J.; Schwartz, J. C. Climbing behavior induced by apomorphine in mice: a simple test for the study of dopamine receptors in striatum. Psychopharmacology 1976, 50, 1-6.
28. Megens, A. A. H. P.; Voeten, J.; Rombouts, J.; Meert, T. F.; Niemegeers, C. J. E. Behavioral activity of rats measured by a new method based on the piezo-electric principle. Psychopharmacology 1987, 93, 382-388.
29. Puech, A. J.; Chermat, R.; Poncelet, M.; Doaré, L.; Simon, P. Antagonism of hypothermia and behavioral response to apomorphine: A simple, rapid and discriminating test for screening antidepressants and neuroleptics. Psychopharmacology 1981, 75, 84-91.
30. Arnt, J.; Christensen, A. V.; Hyttel, J. Differential reversal by scopolamine of effects of neuroleptics in rats. Relevance for evaluation of therapeutic and extrapyramidal side-effect potential. Neuropharmacology 1981, 20, 1331-4.